Research location
L'Hospitalet de Llobregat
Catalonia, Spain
Advertisement
Research activity in L'Hospitalet de Llobregat
Catalonia, SpainCureCurrent currently publishes aggregate city-level research activity for this location: 39 trials and 39 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in L'Hospitalet de Llobregat
39 linked trials · page 1 of 1A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28 · 1 site observation
RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation
RECRUITING
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356 · 2023-11-16 · 1 site observation
RECRUITING
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036 · 2024-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)NCT05853367 · 2023-07-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Psychosocial eHealth in Advanced Lung CancerNCT05497973 · 2022-11-15 · 1 site observation
UNKNOWN
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)NCT05267470 · 2022-03-29 · 1 site observation
TERMINATED
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)NCT05060016 · 2021-12-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation
COMPLETED
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)NCT04938817 · 2021-08-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast CancerNCT04874025 · 2021-07-31 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)NCT04924101 · 2021-07-15 · 1 site observation
COMPLETED
ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATANCT04899206 · 2021-04-12 · 1 site observation
WITHDRAWN
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ANCT03447769 · 2018-03-16 · 1 site observation
TERMINATED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple SclerosisNCT02792218 · 2016-09-20 · 1 site observation
COMPLETED
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)NCT02900664 · 2016-08-23 · 1 site observation
COMPLETED
Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMFNCT02804204 · 2016-06-01 · 1 site observation
UNKNOWN
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDNCT02603393 · 2015-11-20 · 1 site observation
COMPLETED
Long-term Follow-up of Fingolimod Phase II Study PatientsNCT02307838 · 2014-06-01 · 1 site observation
COMPLETED
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal WomenNCT01923168 · 2014-03-11 · 1 site observation
COMPLETED
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast CancerNCT01958021 · 2013-12-17 · 1 site observation
COMPLETED
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerNCT01857193 · 2013-09-06 · 1 site observation
COMPLETED
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerNCT01828099 · 2013-07-09 · 1 site observation
COMPLETED
Clinical Trial on Diabetes Expert Patients ProgrammeNCT01898702 · 2013-05-01 · 1 site observation
UNKNOWN
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K ActivationNCT01572727 · 2012-08-01 · 1 site observation
COMPLETED
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100NCT01605227 · 2012-07-01 · 1 site observation
COMPLETED
Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool.NCT01744028 · 2012-06-01 · 1 site observation
COMPLETED
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative SymptomsNCT01568216 · 2012-05-01 · 1 site observation
TERMINATED
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)NCT01524783 · 2012-03-30 · 1 site observation
COMPLETED
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast CancerNCT01495247 · 2012-01-30 · 1 site observation
TERMINATED
A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsNCT01351103 · 2011-12-01 · 1 site observation
COMPLETED
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneNCT01219699 · 2010-10-05 · 1 site observation
COMPLETED
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisNCT01201356 · 2010-09-13 · 1 site observation
COMPLETED
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes MellitusNCT01171976 · 2010-09-01 · 1 site observation
COMPLETED
ALiskiren or Losartan Effects on bioMARKers of Myocardial RemodelingNCT01176032 · 2010-06-01 · 1 site observation
COMPLETED
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast CancerNCT01132664 · 2010-05-01 · 1 site observation
TERMINATED
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsNCT01120691 · 2010-04-01 · 1 site observation
COMPLETED
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.NCT00731692 · 2008-07-28 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.